Newborn screening programs: Should 22q11 deletion syndrome be added?

Genetics in Medicine

Volumn 12, Issue 3, 2010, Pages 135-144

  Bales, Abigail M ^a   Zaleski, Christina A ^a   McPherson, Elizabeth W ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

Deletion 22q11; DiGeorge syndrome; Newborn screening; Public health; Velocardiofacial syndrome

Indexed keywords

CHROMOSOME 22; CHROMOSOME DELETION; CHROMOSOME DELETION 22Q11; ECONOMICS; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; MULTIPLE MALFORMATION SYNDROME; NEWBORN; NEWBORN SCREENING; REVIEW;

22Q11 DELETION SYNDROME; ABNORMALITIES, MULTIPLE; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING;

EID: 77956998380     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181cdeb9a     Document Type: Review

References (76)

1. Health Professionals Guide to Newborn Screening. Wisconsin Newborn Screening Program, 2008. Available at: http://www.slh.wisc.edu/newborn/nbsguide.pdf. Accessed July 9, 2008.
2. Kerruish NJ, Robertson SP. Newborn screening: new developments, new dilemmas. J Med Ethics 2005;31:393-398.
3. Goodship J, Cross I, Scambler P, Burn J. Monozygotic twins with chromosome 22q11 deletion and discordant phenotype. J Med Genet 1995;32:746-748.
4. Shprintzen RJ. Velo-cardio-facial syndrome. In: Cassidy SB, Allanson JE, editors. Management of genetic syndromes, 2nd ed. Hoboken: Wiley-Liss, 2005:615-631.
5. Ryan AK, Goodship JA, Wilson DI, et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet 1997;34:798-804.
6. Umlauf MG. 22q11 deletion syndrome: is that what they used to call? Perspect Psychiatr Care 2008;44:259-266.
7. McDonald-McGinn D, Emanuel B, Zackai E. 22q11.2 deletion syndrome. Gene Reviews Web site, 1998. Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=gr_22q11deletion. Accessed June 11, 2009.
8. Oskarsdóttir S, Vujic M, Fasth A. Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden. Arch Dis Child 2004;89:148-151.
9. Botto LD, May K, Fernhoff PM, et al. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 2003;112:101-107.
10. Burn J, Wilson DI, Cross I, et al. The clinical significance of 22q11 deletion. In: Clark EB, Markwald RR, Takao A, editors. Developmental mechanisms of heart disease. Armonk, NY: Blackwell/Futura, 1995:559.
11. McDonald-McGinn DM, Minugh-Purvis N, Kirschner RE, et al. The 22q11.2 deletion in African-American patients: an underdiagnosed population? Am J Med Genet A 2005;134:242-246.
12. Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 2007;370:1443-1452.
13. Hay BN. Deletion 22q11: spectrum of associated disorders. Semin Pediatr Neurol 2007;14:136-139.
14. Goldmuntz E, Clark BJ, Mitchell LE, et al. Frequency of 22q11 deletions in patients with conotruncal defects. J Am Coll Cardiol 1998;32:492-498.
15. Park MK, MD. Pediatric cardiology for practitioners, 5th ed. Philadelphia, PA: Mosby Elsevier, 2008:680. Available at: http://www.amazon.com/Pediatric-Cardiology-Practitioners-Myung-Park/dp/0323046363. Accessed May 29, 2009.
16. Carotti A, Digilio MC, Piacentini G, Saffirio C, Di Donato RM, Marino B. Cardiac defects and results of cardiac surgery in 22q11.2 deletion syndrome. Dev Disabil Res Rev 2008;14:35-42.
17. Knowles R, Griebsch I, Dezateux C, Brown J, Bull C, Wren C. Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis. Health Technol Assess 2005;9:1-152, iii-iv.
18. Wren C, Richmond S, Donaldson L. Presentation of congenital heart disease in infancy: implications for routine examination. Arch Dis Child Fetal Neonatal Ed 1999;80:F49-F53.
19. McLean-Tooke A, Spickett GP, Gennery AR. Immunodeficiency and autoimmunity in 22q11.2 deletion syndrome. Scand J Immunol 2007;66:1-7.
20. Jawad AF, McDonald-Mcginn DM, Zackai E, Sullivan KE. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr 2001;139:715-723.
21. Sullivan KE, McDonald-McGinn D, Driscoll DA, Emanuel BS, Zackai EH, Jawad AF. Longitudinal analysis of lymphocyte function and numbers in the first year of life in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Diagn Lab Immunol 1999;6:906-911.
22. Finocchi A, Di Cesare S, Romiti ML, et al. Humoral immune responses and CD27+ B cells in children with DiGeorge syndrome (22q11.2 deletion syndrome). Pediatr Allergy Immunol 2006;17:382-388.
23. Perez E, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge and velocardiofacial syndromes). Curr Opin Pediatr 2002;14:678-683.
24. Gennery AR, Barge D, O’Sullivan JJ, Flood TJ, Abinun M, Cant AJ. Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome. Arch Dis Child 2002;86:422-425.
25. Kitsiou-Tzeli S, Kolialexi A, Mavrou A. Endocrine manifestations in DiGeorge and other microdeletion syndromes related to 22q11.2. Hormones (Athens) 2005;4:200-209.
26. McDonald-McGinn DM, Kirschner R, Goldmuntz E, et al. The Philadelphia story: the 22q11.2 deletion: report on 250 patients. Genet Couns 1999;10:11-24.
27. Cuneo BF, Driscoll DA, Gidding SS, Langman CB. Evolution of latent hypoparathyroidism in familial 22q11 deletion syndrome. Am J Med Genet 1997;69:50-55.
28. Kao A, Mariani J, McDonald-McGinn DM, et al. Increased prevalence of unprovoked seizures in patients with a 22q11.2 deletion. Am J Med Genet A 2004;129A:29-34.
29. Weinzimer SA, McDonald-McGinn DM, Driscoll DA, Emanuel BS, Zackai EH, Moshang T Jr. Growth hormone deficiency in patients with 22q11.2 deletion: expanding the phenotype. Pediatrics 1998;101:929-932.
30. Weinzimer SA. Endocrine aspects of the 22q11.2 deletion syndrome. Genet Med 2001;3:19-22.
31. Brauner R, Le Harivel de Gonneville A, Kindermans C, et al. Parathyroid function and growth in 22q11.2 deletion syndrome. J Pediatr 2003;142:504-508.
32. Oskarsdóttir S, Holmberg E, Fasth A, Strömland K. Facial features in children with the 22q11 deletion syndrome. Acta Paediatr 2008;97:1113-1117.
33. Goldmuntz E. DiGeorge syndrome: new insights. Clin Perinatol 2005;32:963-978, ix-x.
34. Dyce O, McDonald-McGinn D, Kirschner RE, Zackai E, Young K, Jacobs IN. Otolaryngologic manifestations of the 22q11.2 deletion syndrome. Arch Otolaryngol Head Neck Surg 2002;128:1408-1412.
35. Eicher PS, McDonald-Mcginn DM, Fox CA, Driscoll DA, Emanuel BS, Zackai EH. Dysphagia in children with a 22q11.2 deletion: unusual pattern found on modified barium swallow. J Pediatr 2000;137:158-164.
36. Oskarsdóttir S, Persson C, Eriksson BO, Fasth A. Presenting phenotype in 100 children with the 22q11 deletion syndrome. Eur J Pediatr 2005;164:146-153.
37. Roizen NJ, Antshel KM, Fremont W, et al. 22q11.2DS deletion syndrome: developmental milestones in infants and toddlers. J Dev Behav Pediatr 2007;28:119-124.
38. Gerdes M, Solot C, Wang PP, et al. Cognitive and behavior profile of preschool children with chromosome 22q11.2 deletion. Am J Med Gene 1999;85:127-133.
39. Solot CB, Knightly C, Handler SD, et al. Communication disorders in the 22Q11.2 microdeletion syndrome. J Commun Disord 2000;33:187-203; quiz 203-204.
40. Gerdes M, Solot C, Wang PP, McDonald-McGinn DM, Zackai EH. Taking advantage of early diagnosis: preschool children with the 22q11.2 deletion. Genet Med 2001;3:40-44.
41. Niklasson L, Rasmussen P, Oskarsdóttir S, Gillberg C. Autism, ADHD, mental retardation and behavior problems in 100 individuals with 22q11 deletion syndrome. Res Dev Disabil 2009;30:763-773.
42. Shprintzen RJ, Goldberg R, Golding-Kushner KJ, Marion RW. Late-onset psychosis in the velo-cardio-facial syndrome. Am J Med Genet 1992;42:141-142.
43. Bassett AS, Chow EW. Schizophrenia and 22q11.2 deletion syndrome. Curr Psychiatry Rep 2008;10:148-157.
44. Arinami T. Analyses of the associations between the genes of 22q11 deletion syndrome and schizophrenia. J Hum Genet 2006;51:1037-1045.
45. Gothelf D, Frisch A, Munitz H, et al. Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome. Schizophr Res 1999;35:105-112.
46. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999;56:940-945.
47. Vorstman JA, Morcus ME, Duijff SN, et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. J Am Acad Child Adolesc Psychiatry 2006;45:1104-1113.
48. Baker KD, Skuse DH. Adolescents and young adults with 22q11 deletion syndrome: psychopathology in an at-risk group. Br J Psychiatry 2005;186:115-120.
49. Rapoport J, Chavez A, Greenstein D, Addington A, Gogtay N. Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited. J Am Acad Child Adolesc Psychiatry 2009;48:10-18.
50. Fine SE, Weissman A, Gerdes M, et al. Autism spectrum disorders and symptoms in children with molecularly confirmed 22q11.2 deletion syndrome. J Autism Dev Disord 2005;35:461-470.
51. Kates WR, Antshel KM, Fremont WP, et al. Comparing phenotypes in patients with idiopathic autism to patients with velocardiofacial syndrome (22q11DS) with and without autism. Am J Med Genet A 2007;143A:2642-2650.
52. Gothelf D, Michaelovsky E, Frisch A, et al. Association of the low-activity COMT 158Met allele with ADHD and OCD in subjects with velocardiofacial syndrome. Int J Neuropsychopharmacol 2007;10:301-308.
53. Gothelf D. Velocardiofacial syndrome. Child Adolesc Psychiatr Clin N Am 2007;16:677-693.
54. Kyburz A, Bauersfeld U, Schinzel A, et al. The fate of children with microdeletion 22q11.2 syndrome and congenital heart defect: clinical course and cardiac outcome. Pediatr Cardiol 2008;29:76-83.
55. Formigari R, Michielon G, Digilio MC, et al. Genetic syndromes and congenital heart defects: how is surgical management affected? Eur J Cardiothorac Surg 2009;35:606-614.
56. Atallah J, Joffe AR, Robertson CM, et al. Two-year general and neurodevelopmental outcome after neonatal complex cardiac surgery in patients with deletion 22q11.2: a comparative study. J Thorac Cardiovasc Surg 2007;134:772-779.
57. Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 2003;112:e325.
58. Moylett EH, Wasan AN, Noroski LM, Shearer WT. Live viral vaccines in patients with partial DiGeorge syndrome: clinical experience and cellular immunity. Clin Immunol 2004;112:106-112.
59. Shprintzen RJ. Velo-cardio-facial syndrome: 30 Years of study. Dev Disabil Res Rev 2008;14:3-10.
60. DiGeorge/Velo-cardio-facial/Shprintzen/Conotruncal anomaly syndrome, Deletion 22q11.2, TUPLE1, FISH, for Genetic Diagnosis. UW Cytogenetic Services Web site, 2009. Available at: http://www.slh.wisc.edu/outreach/wslhGuide/wslhSearch.php?searchTerm=22q11&TEST_REFERENCE_ID=6579&submitIt=testDetail. Accessed July 24, 2009.
61. Wentzel C, Fernström M, Ohrner Y, Annerén G, Thuresson AC. Clinical variability of the 22q11.2 duplication syndrome. Eur J Med Genet 2008;51:501-510.
62. Hoffman GL, Laessig RH. Screening newborns for congenital disorders. WMJ 2003;102:45-50.
63. Parsons EP, Clarke AJ, Hood K, Lycett E, Bradley DM. Newborn screening for Duchenne muscular dystrophy: a psychosocial study. Arch Dis Child Fetal Neonatal Ed 2002;86:F91-F95.
64. Baroni MA, Anderson YE, Mischler E. Cystic fibrosis newborn screening: impact of early screening results on parenting stress. Pediatr Nurs 1997;23:143-151.
65. Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochem-ical genetic disorders on child outcomes and parental stress. JAMA 2003;290:2564-2572.
66. Tluczek A, Koscik RL, Farrell PM, Rock MJ. Psychosocial risk associated with newborn screening for cystic fibrosis: parents’ experience while awaiting the sweat-test appointment. Pediatrics 2005;115:1692-1703.
67. Kokotos F. The vulnerable child syndrome. Pediatr Rev 2009;30:193-194.
68. Meltzer HY, Bobo WV, Heckers SH, Fatemi HS. Schizophrenia. In: Ebert MH, Loosen PT, Nurcombe B, Leckman JF, editors. Current diagnosis and treatment psychiatry, 2nd ed. New York: McGraw-Hill Medical, 2008:261.
69. Malpas PJ. Why tell asymptomatic children of the risk of an adult-onset disease in the family but not test them for it? J Med Ethics 2006;32:639-642.
70. Hercher L, Bruenner G. Living with a child at risk for psychotic illness: the experience of parents coping with 22q11 deletion syndrome: an exploratory study. Am J Med Genet A 2008;146A:2355-2360.
71. Clarke M, O’Callaghan E. Is earlier better? At the beginning of schizophrenia: timing and opportunities for early intervention. Psychiatr Clin North Am 2003;26:65-83.
72. Griebsch I, Knowles RL, Brown J, Bull C, Wren C, Dezateux CA. Comparing the clinical and economic effects of clinical examination, pulse oximetry, and echocardiography in newborn screening for congenital heart defects: a probabilistic cost-effectiveness model and value of information analysis. Int J Technol Assess Health Care 2007;23:192-204.
73. van Calcar SC, Gleason LA, Lindh H, et al. 2-methylbutyryl-CoA dehydrogenase deficiency in Hmong infants identified by expanded newborn screen. WMJ 2007;106:12-15.
74. Farrell PM, Li Z, Kosorok MR, et al. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit Care Med 2003;168:1100-1108.
75. Watson MS, Lloyd-Puryear MA, Mann MY, Rinaldo P, Howell RR. Newborn screening: toward a uniform screening panel and system. Genet Med 2006;8(suppl 1):1S-252S.
76. Digilio MC, Marino B, Giannotti A, Mingarelli R, Dallapiccola B. Guidelines for 22q11 deletion screening of patients with conotruncal defects. J Am Coll Cardiol 1999;33:1746-1748.